{"ticker": {"uuid": "9a30357b-b675-44d2-a718-66a249dcb4be", "symbol": "JANX", "name": "Janux Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Avoiding Lag: Real-Time Signals in (JANX) Movement", "summary": "This article provides a real-time stock analysis for Janux Therapeutics Inc. (NASDAQ: JANX), indicating near-term weak sentiment but mid-term strength within a broader long-term weak bias. It highlights specific resistance and support levels, along with three AI-generated trading", "url": "https://news.stocktradersdaily.com/news_release/40/Avoiding_Lag:_Real-Time_Signals_in_JANX_Movement_071926042401_1784492641.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-19T16:41:43", "published_display": "19 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (JANX) Gains Momentum: Biotech Stock Rises 2.65% as Buyers Test Key Resistance - IPO Entry Watch", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPaU11Q3c5b2Z5RXFFeW9TRFl5ZllPNjlUV3hSZHN4VDROdFMwWmVjUTdfZEJ1SHQ3NzdUVVhFQkNzeWp6bFM1TnUtRm9LbVFhYUxYWld1eWpCLVVjbFR1T2lSc2xRMm1nYTdLZjlXczhTT1FvZHlWOUhmMUd4S3daMzJHRzZDT2FqYWRhelA3MEI1V3k1WjBGRGh4c0FhWUhTbl8tcjB0VjJoaFBXTXBPeWxvdEFuajlNMVQ5aGJCNkJNdmh1Yk1VUWN2ZkdVc1k?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-18T00:48:15+00:00", "published_display": "18 Jul 2026 00:48", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Janux Therapeutics (NASDAQ: JANX) CEO exercises 7,000 options at $4.21, boosts holdings", "summary": "Janux Therapeutics President and CEO David Alan Campbell exercised stock options to acquire 7,000 shares of common stock at an exercise price of $4.21 per share. This transaction, which occurred on July 8, 2026, increased his direct holdings to 388,582 common shares, while he sti", "url": "https://www.stocktitan.net/sec-filings/JANX/form-4-janux-therapeutics-inc-insider-trading-activity-9cc1681db5ee.html", "source_name": "Stock Titan", "published_at": "2026-07-11T05:39:28", "published_display": "11 Jul 2026 05:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Janux Therapeutics\u2019 (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQU1FxMXU2Um5MaGRBdGdTVnNzbUdVVXR3eTVaSHFZYWhBYll1Y1otc0UwQzl5ekZCSXMtYVR5cHF2bmh3M0VKUUF5clpBX2VTY0ZQZTQ3UmhDRFB4T21pMWNKbFhpR056LXNTZWt0U2ZJZEpfanp2T3hpNVZBLTltSFpPVXBQSFZEOGhLcDJTaWZXN2dNYnBhbmR6eHZmZGFMRXdobg?oc=5", "source_name": "Market source", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (JANX) Is Up 13.6% After Removal From Multiple Russell Growth Indexes - What's Changed", "summary": "Janux Therapeutics (JANX) shares rose 13.6% despite its recent removal from several Russell growth benchmarks, including the Russell 3000 and 2000. The article suggests this removal is a technical detail affecting liquidity and investor base rather than fundamental business chang", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-janx/janux-therapeutics/news/janux-therapeutics-janx-is-up-136-after-removal-from-multipl", "source_name": "Simply Wall Street", "published_at": "2026-07-09T03:11:17", "published_display": "09 Jul 2026 03:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Janux Therapeutics, Inc. \u2013 NASDAQ:JANX", "summary": "The article focuses on the \"Price to sales forward\" metric for Janux Therapeutics, Inc. (NASDAQ: JANX). It appears to be a financial data page from TradingView, providing an overview of the company's financial information, technical analysis, and market data. The content is prima", "url": "https://www.tradingview.com/symbols/NASDAQ-JANX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T03:40:15", "published_display": "04 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Janux Therapeutics, Inc. \u2013 NASDAQ:JANX", "summary": "This article provides financial information for Janux Therapeutics, Inc. (NASDAQ: JANX) focusing on its price to earnings forward metric. The content highlights a specific period, its value, and the percentage change. It appears to be an excerpt from a financial data platform lik", "url": "https://www.tradingview.com/symbols/NASDAQ-JANX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T21:39:22", "published_display": "03 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/janux-therapeutics-inc-janx-stock-130639551.html", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:06:39+00:00", "published_display": "30 Jun 2026 13:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2500 Growth Benchmark", "summary": "Janux Therapeutics, Inc. (JANX) has been removed from the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth, Russell 3000E Growth, and Russell Small Cap Comp Growth benchmarks. This news follows a series of recent updates including leadership changes, analyst pric", "url": "https://www.marketscreener.com/news/janux-therapeutics-inc-nasdaqgm-janx-dropped-from-russell-2500-growth-benchmark-ce7f5fdfdd89ff27", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:50:00", "published_display": "29 Jun 2026 19:50", "sentiment": "negative", "sentiment_pct": 32, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 3000 Growth Benchmark", "summary": "Janux Therapeutics, Inc. (NasdaqGM: JANX) has been removed from the Russell 3000 Growth Benchmark, as well as the Russell 2500, Russell 2000, and Russell 3000E Growth Benchmarks. This news follows several other recent updates for the company, including leadership changes, adjuste", "url": "https://www.marketscreener.com/news/janux-therapeutics-inc-nasdaqgm-janx-dropped-from-russell-3000-growth-benchmark-ce7f5fdcd188f72d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:09:47", "published_display": "29 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2000 Growth Benchmark", "summary": "Janux Therapeutics, Inc. (NasdaqGM:JANX) has been removed from the Russell 2000 Growth Benchmark as of June 29, 2026. The biopharmaceutical company is currently developing tumor-activated immunotherapies for cancer, utilizing its TRACTr, TRACIr, and ARM bispecific platforms. This", "url": "https://www.marketscreener.com/news/janux-therapeutics-inc-nasdaqgm-janx-dropped-from-russell-2000-growth-benchmark-ce7f5fded188f223", "source_name": "marketscreener.com", "published_at": "2026-06-29T11:41:50", "published_display": "29 Jun 2026 11:41", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Most Promising Cancer Stocks According to Wall Street Analysts", "summary": "This article identifies five promising cancer stocks according to Wall Street analysts, focusing on companies with significant price target upsides and pipeline developments. It highlights Janux Therapeutics, Inc. (NASDAQ:JANX) as one such company, detailing analyst ratings, its ", "url": "https://www.insidermonkey.com/blog/5-most-promising-cancer-stocks-according-to-wall-street-analysts-1790774/", "source_name": "Insider Monkey", "published_at": "2026-06-28T17:10:18", "published_display": "28 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in JANX Response", "summary": "Stock Traders Daily's Quantitative Research Desk has analyzed Janux Therapeutics Inc. (NASDAQ: JANX), identifying strong near and mid-term sentiment but a weak long-term outlook. The analysis highlights an exceptional risk-reward short setup targeting a 29.6% downside with minima", "url": "https://news.stocktradersdaily.com/news_release/34/Discipline_and_Rules-Based_Execution_in_JANX_Response_062726075202_1782561122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-27T07:40:36", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JANX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Janux Therapeutics, Inc. (JANX) stock for 2027, based on analyst ratings and estimates. It includes current stock performance data, financial metrics like revenue and earnings, and answers frequently asked questions about the c", "url": "https://www.tradingview.com/symbols/NASDAQ-JANX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T11:09:49", "published_display": "26 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics, Inc. Actuals & Estimates (NASDAQ:JANX)", "summary": "This article provides an overview of Janux Therapeutics, Inc. (NASDAQ: JANX) stock, including its current price, performance, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue for past quarters, and also provides upcoming ea", "url": "https://www.tradingview.com/symbols/NASDAQ-JANX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:49", "published_display": "26 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX)", "summary": "Healthcare analysts have issued bullish sentiments for Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX). Debanjana Chatterjee from JonesTrading reiterated a Buy rating for Sionna with a $63.00 price target, while Supawat Thongthip from Truist Financial gave Janu", "url": "https://www.theglobeandmail.com/investing/markets/stocks/JANX/pressreleases/17357/analysts-offer-insights-on-healthcare-companies-sionna-therapeutics-inc-sion-and-janux-therapeutics-inc-janx/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T08:52:00", "published_display": "26 Jun 2026 08:52", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $26", "summary": "Truist Financial has initiated coverage on Janux Therapeutics (JANX.US) with a Buy rating. The firm has set a target price of $26 for the company's shares. This indicates a positive outlook from Truist Financial regarding Janux Therapeutics' future performance.", "url": "https://www.moomoo.com/news/post/72044984/truist-financial-initiates-janux-therapeutics-janxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-26T00:40:36", "published_display": "26 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (NasdaqGM:JANX) Stock Forecast & Analyst Predictions", "summary": "Janux Therapeutics (JANX) is forecast to experience a decline in earnings at 16.8% per annum, while revenue is expected to grow by 47.7% annually. The company, which is currently unprofitable, has seen various price target changes and estimate revisions from analysts. Recent upda", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-janx/janux-therapeutics/future", "source_name": "Simply Wall Street", "published_at": "2026-06-25T13:41:50", "published_display": "25 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Janux Therapeutics Inc For: 23 June By Investing.com", "summary": "This article announces that Janux Therapeutics Inc. filed a Form 8K for June 23. This is a brief notice from Investing.com, highlighting the company's regulatory filing. The notice includes their stock symbol JANX and its recent performance.", "url": "https://au.investing.com/news/stock-market-news/form-8k-janux-therapeutics-inc-for-23-june-93CH-4501037", "source_name": "Investing.com Australia", "published_at": "2026-06-24T23:41:45", "published_display": "24 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMO exits Janux Therapeutics (NASDAQ: JANX) as company starts search", "summary": "Janux Therapeutics announced the departure of its Chief Medical Officer, William Go, M.D., Ph.D., on June 23, 2026. The company stated his departure was a termination without \"Cause\" and does not reflect any disagreement over operations or strategy. Janux will begin a search for ", "url": "https://www.stocktitan.net/sec-filings/JANX/8-k-janux-therapeutics-inc-reports-material-event-a78f4c35970f.html", "source_name": "Stock Titan", "published_at": "2026-06-23T19:40:17", "published_display": "23 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Inc (JANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on Janux Therapeutics Inc. (JANX)'s revenue breakdown, but states that the relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It provides current stock information fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-janx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:11:31", "published_display": "17 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides an overview of Janux Therapeutics Inc. (JANX) regarding its dividends and stock splits. It states that the company has not distributed any dividends over the past five years and has no historical stock split data available. Financial data for JANX, including ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-janx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:11:31", "published_display": "17 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Inc (JANX) Institutional Confidence", "summary": "Janux Therapeutics Inc (JANX) has an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 110.21%, showing a 0.64% increase quarter-over-quarter. Steven Cohen", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-janx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T23:10:58", "published_display": "16 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Inc (JANX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Janux Therapeutics Inc (JANX) has a risk assessment score of 2.93, ranking 175 out of 388 in the Biotechnology & Medical Research industry, with a beta of 2.54 indicating higher volatility than the S&P 500. The company's risk profile includes a 240-day maximum drawdown of +64.94%", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-janx/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-16T23:09:46", "published_display": "16 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JANX SEC Filings - Janux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Janux Therapeutics (JANX) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It highlights recent filings such as Janus Henderson's passive ownership report, Adage Capital's stake", "url": "https://www.stocktitan.net/sec-filings/JANX/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-15T00:10:03", "published_display": "15 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Reports Results of 2026 Annual Meeting", "summary": "Janux Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026, where shareholders elected two Class II directors, ratified Ernst & Young LLP as the independent accounting firm, and approved executive compensation. The company's stock, JANX, currently hold", "url": "https://www.theglobeandmail.com/investing/markets/stocks/JANX/pressreleases/2458085/janux-therapeutics-reports-results-of-2026-annual-meeting/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T09:40:46", "published_display": "14 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (JANX) director reports RSU and option awards tied to RA Capital", "summary": "Janux Therapeutics director Jake Simson reported receiving 5,500 restricted stock units (RSUs) and options for 15,500 shares, with vesting tied to continuous service. These equity awards are held for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund II, aligning", "url": "https://www.stocktitan.net/sec-filings/JANX/form-4-janux-therapeutics-inc-insider-trading-activity-c7f52f7a8e0b.html", "source_name": "Stock Titan", "published_at": "2026-06-13T06:40:20", "published_display": "13 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (JANX) director awarded RSUs and stock options", "summary": "Janux Therapeutics director Natasha Hernday received 5,500 restricted stock units (RSUs) and stock options for 15,500 shares. The RSUs vest by June 11, 2027, or the next annual stockholder meeting, while the stock options vest monthly over 12 months from June 11, 2026, both subje", "url": "https://www.stocktitan.net/sec-filings/JANX/form-4-janux-therapeutics-inc-insider-trading-activity-b29ae949f07b.html", "source_name": "Stock Titan", "published_at": "2026-06-13T06:40:20", "published_display": "13 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director of Janux Therapeutics (JANX) receives new RSU and stock option awards", "summary": "Winston Kung, a director at Janux Therapeutics (JANX), has received new equity awards comprising 5,500 restricted stock units (RSUs) and 15,500 stock options with an exercise price of $13.66 per share. The RSUs are set to vest by June 11, 2027, or the next annual stockholder meet", "url": "https://www.stocktitan.net/sec-filings/JANX/form-4-janux-therapeutics-inc-insider-trading-activity-2d58852db0b3.html", "source_name": "Stock Titan", "published_at": "2026-06-13T00:10:09", "published_display": "13 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Janux Therapeutics (JANX) gets new RSUs and stock options", "summary": "Janux Therapeutics director Vickie L. Capps was granted 5,500 restricted stock units (RSUs) and options for 15,500 shares of common stock at an exercise price of $13.66 per share. Following these awards, her direct holdings increased to 79,598 shares. The RSUs and stock options a", "url": "https://www.stocktitan.net/sec-filings/JANX/form-4-janux-therapeutics-inc-insider-trading-activity-1220f455fb5c.html", "source_name": "Stock Titan", "published_at": "2026-06-13T00:10:09", "published_display": "13 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Highlights 1st ASCO Abstract Acceptance", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/akari-therapeutics-highlights-1st-asco-223346398.html", "source_name": "IPO-Edge.com", "published_at": "2026-05-28T22:33:46+00:00", "published_display": "28 May 2026 22:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPTWhweV9vbVpoeFI4NGRyYzhDT1JRNVEzV1g1V2ZXTndlLWVpQmk2OGs1czczT3lORVphM1pCUDF1OUl5ZGtEamdmdHpEQW10aXlYVUdEaGxUd0RuLU44cmVtY0I5eFdqSXVsR1c1T2VHYlZfS1k1MUp4enVPX2ZZRk5BTUYzdy10VFVJT1ZLeHRhZUxFRGtDM0ZVdEpRZw?oc=5", "source_name": "Market source", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Janux Therapeutics (JANX) Losses Reach US$113.6 Million TTM Reinforcing Bearish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Raises Janux Therapeutics Price Target to $30 From $27, Keeps Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-raises-janux-therapeutics-price-164408818.html", "source_name": "MT Newswires", "published_at": "2026-05-08T16:44:08+00:00", "published_display": "08 May 2026 16:44", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNSXdZWlVkX2xXcnZBeDFzZ09YY0pqUTJDVE8xSjh2WXl6dk16c3NucHhzcUU5ZHRpRzZuNDlRSHBUb0VHc0dpQ1VJbFdJMDNxaGdhbktwbkU3X24yYnJnMHJ5WjB0S25MbmEyd3NqdHIxTjBkckFvV1IzU2ZoLUlraUhmdGtlWnYtWEc1U1lGUHRQQVF0Z0ZwdkxKN0pQNzUwRjlBOUpnSVgyQVNzWERiT09uNVRLM2ZLb0NRME13elphUQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPN2syQVVRcm85Q1BsNUtQeDN1aUNVMGFvYmNjZG9YdW9MTjFzUXp1RnkzemtaUkNfRXBuZFd0Z2xtb1gxUk1BNkpBU094dDlEMGJ4UE9ZR29tbktnajlyeUhmSGNXT2pCRWZlZ1BWMU9lbU5nM0ZQSmR3YWI3T29jREE0enhFdlpQRXVNY1JhamtVbko0WFdfYVlDMmtsRk1lU3BYN01ydG4tRlY0cUl5ejc2ZV9kMF9qM3FFMHRYczBvYy1xdndkZ2FOeWdobXFLOVlORUFEVU5DOEhI?oc=5", "source_name": "Business Wire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOOFJuQmxYRk8wdnlkX0ZDamRNXy16OUg1YzZqMTQ1eVZhZm5tSmFzUmVsOGVfSk94VS11THNBOEc5THZDY18tUC0xTU5SMlZmdklOQXFLbjRteXRNRVk5RWtlbUtJQ0F2QWxMdmwtS1NVTE5LdjFncmFkTzctcFNCN19GWXpjQ1pQaFFJRTd3akVVcTVFT09jUy1fX2dmN3J1Q1JtS0J1aw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMWRJSnQ2LUp0NDdNZkhFcTg2dzliZHVLSFVpamFRY1ZHOXlBa0dEcHkwcFZPTWRySWN6X1RPVXZoUTZLcXR3NjNzbmZRbzRmY2NSN3N2Yl90ZEZscDBjWmNhVWUyRW1UdGgtZC1EWmllOE5jVmF3MWhuek9oRHgtMWZPRWxfZENfdFFxQ3VLZUNmZTNVemtob0pXdXowcmFuYkpqQUlEVGxTeU9MTlp4OEVkbHZEdmdKTVhZbFN3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Multiple Insiders Sold Janux Therapeutics Shares Presenting Weak Signs For Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux drops JANX008 cancer program after Phase 1a data review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQXZzTVlRaGl5R2E3Q3BwWnljdlgtUm03NFMwN041OGVtSDZvTW8tREgxWTUwQkt1VmozLVJuSkxWZVFSUEVYVXlibVNSN1FaQUtZbG5VTFRiUHJKQTBZZUU4THlGWTJ0Mk02MUF6T2NnbEg3QmRpSjdaRXpSLW13TWZkc2lfTU5MaEhQNE1PeUdjTnB1M1d4YU1hZnNkV1FpSHMtYTdBWmNOMWxZMFBSR2l5dlYtRmY1TldB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "New prostate cancer drug candidate enters first human trial at Janux", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNdjNfZWwtbXVfQ2tlOGwzVnFFeFo2N2steDE0c2xsTzc5eXhsXzc5emY3S2MyQzVudWFmcXJFdExPMFNKaGlxTG5kaVcyMktHR1BsYi0ySTVmWTl5RGl0dklMeUNhaF9TRVF1X3ZxbC1TbWNqOGlyY0Z5M1VBa3NtVzZxeUxkUXQ2N0lkd2p3R1Q4TVJMZkJGTEp2ZHVTOHJLTC1ib05XYnhCNUpKTnM1cVpCR0RLQ3djZUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Secures $35M Milestone Payment From BMY Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNVk1DYjc2M2FKREdCeXg4WmNwRTZwUEg5TWlYRUJvOEU2bGJpaTFQc25iMzFrTjRCOWROamFvQjNPcG1sNXY5LVdRV0RoMVNhMlZFeFpxNzJ5aUpSV3RtMWlfNjY0M0lrZFlRbFo5S3JZNVhtQWhsQXZKZnMtMkpDMmxJa2pVUEFscHR0UlVfVXpuSGhfZTRBa1ZWX2stY1FabzZsRTdFUVhqT2F1bkE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Where is Janux Therapeutics (JANX) Headed According to Analysts?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOR3FTMDlSUE1uYXcySDV5WVd0WWgzbnQ5RUN3YmtvWGN3cjVIMlRFOTJidHlleGk1bFNKUkNFcTM2QzQtZGJGdjJfX0FFcGRaTEU2bjhoRVlVeTBHODNET0FLU1hHTDJPY0lMc3I0VEtsaDNrbV9SUFhtbVcwZlR2V2NibzBJUlhEb3c?oc=5", "source_name": "Market source", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNNVZ6LVNlY0k3S284VzdUUzJPSFhpRFgwLVF3R2JHMlNzOEpNbTg2ZjhNdXhaT1JFLVpMbXdVTFNFeUFtbHhwZHM4UkJLWktrbHpOaXpHNWZ2YnJVaXdTM3Z0cHJjam9QNjdjR1ktRkVndTVxUWdOS2FjVVRSUktLQWRGcnJHcVB0bGR1Y0pGR25tZkdjckNCUVV2Qjc5VEFYS290UDlBaVRSbFNXRnBjVng3TFVUM1dtOWV1X0l2ZUo?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-22T13:03:08+00:00", "published_display": "22 Jan 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reassessing Janux Therapeutics (JANX) Valuation After Mixed Market Reaction to New JANX007 Phase 1 Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street \u2014 Retail Sees A FOMO-Fueled Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNNThHY25iWWdmYUJ6a1Q1Um1FcjZKVkFwYS1BS3R3Q0FTc3JCSjVHYWRVVG5zLVhqSzdua3Q4cDV1SGFmbGY5NHlPQVI2Rkx6V0JCQUVJeW1nTWk3T0dRZ1hVeUpsUTdPVG95Vm9XVHhhNTh3TWNiX2hiNTBtOE4xX1daaUxEVzlBQTlDZVdXZ0JmZG1xTFBqazlrNnRudUFpdzY5MUpTNldUVjc2cGdFQ1RjMjdfM0JNU0ZraloxR1Y2WFJpLXBrOWpwcVk3TEx0S3BESWNMQUY2OEVWNHp5dDlHU3JtSXdFVkVxN1Jocm1mNU0wZmptUA?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-02T16:38:25+00:00", "published_display": "02 Dec 2025 16:38", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (JANX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE84bFB5ZklSR2ZoTkRGVklIMmlSbjI4ZVdNc0prMUp4aDBkY0dGU2tsVEdadDRuclhELXRXWTN4WDBtNUlJSzUtLU1NaFg4cEhJcjBj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:19:23+00:00", "published_display": "25 Apr 2025 01:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JANX Stock Price and Chart \u2014 NASDAQ:JANX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE11RlkzUjc4b28xYjMwMEtCQ1Y2ZHh2ZUtfQjYtMEIxNm16cURCRVFUWGdGZ1FJVlRSUm53ZUJtbHNONlZOdVA1TDE1bEJXNno4WWZlQXRGNGtXem9R?oc=5", "source_name": "TradingView", "published_at": "2021-06-11T02:37:11+00:00", "published_display": "11 Jun 2021 02:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Avoiding Lag: Real-Time Signals in (JANX) Movement", "summary": "This article provides a real-time stock analysis for Janux Therapeutics Inc. (NASDAQ: JANX), indicating near-term weak sentiment but mid-term strength within a broader long-term weak bias. It highlights specific resistance and support levels, along with three AI-generated trading", "url": "https://news.stocktradersdaily.com/news_release/40/Avoiding_Lag:_Real-Time_Signals_in_JANX_Movement_071926042401_1784492641.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-19T16:41:43", "published_display": "19 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (JANX) Gains Momentum: Biotech Stock Rises 2.65% as Buyers Test Key Resistance - IPO Entry Watch", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPaU11Q3c5b2Z5RXFFeW9TRFl5ZllPNjlUV3hSZHN4VDROdFMwWmVjUTdfZEJ1SHQ3NzdUVVhFQkNzeWp6bFM1TnUtRm9LbVFhYUxYWld1eWpCLVVjbFR1T2lSc2xRMm1nYTdLZjlXczhTT1FvZHlWOUhmMUd4S3daMzJHRzZDT2FqYWRhelA3MEI1V3k1WjBGRGh4c0FhWUhTbl8tcjB0VjJoaFBXTXBPeWxvdEFuajlNMVQ5aGJCNkJNdmh1Yk1VUWN2ZkdVc1k?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-18T00:48:15+00:00", "published_display": "18 Jul 2026 00:48", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (NASDAQ: JANX) CEO exercises 7,000 options at $4.21, boosts holdings", "summary": "Janux Therapeutics President and CEO David Alan Campbell exercised stock options to acquire 7,000 shares of common stock at an exercise price of $4.21 per share. This transaction, which occurred on July 8, 2026, increased his direct holdings to 388,582 common shares, while he sti", "url": "https://www.stocktitan.net/sec-filings/JANX/form-4-janux-therapeutics-inc-insider-trading-activity-9cc1681db5ee.html", "source_name": "Stock Titan", "published_at": "2026-07-11T05:39:28", "published_display": "11 Jul 2026 05:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Janux Therapeutics\u2019 (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQU1FxMXU2Um5MaGRBdGdTVnNzbUdVVXR3eTVaSHFZYWhBYll1Y1otc0UwQzl5ekZCSXMtYVR5cHF2bmh3M0VKUUF5clpBX2VTY0ZQZTQ3UmhDRFB4T21pMWNKbFhpR056LXNTZWt0U2ZJZEpfanp2T3hpNVZBLTltSFpPVXBQSFZEOGhLcDJTaWZXN2dNYnBhbmR6eHZmZGFMRXdobg?oc=5", "source_name": "Market source", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (JANX) Is Up 13.6% After Removal From Multiple Russell Growth Indexes - What's Changed", "summary": "Janux Therapeutics (JANX) shares rose 13.6% despite its recent removal from several Russell growth benchmarks, including the Russell 3000 and 2000. The article suggests this removal is a technical detail affecting liquidity and investor base rather than fundamental business chang", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-janx/janux-therapeutics/news/janux-therapeutics-janx-is-up-136-after-removal-from-multipl", "source_name": "Simply Wall Street", "published_at": "2026-07-09T03:11:17", "published_display": "09 Jul 2026 03:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Janux Therapeutics, Inc. \u2013 NASDAQ:JANX", "summary": "The article focuses on the \"Price to sales forward\" metric for Janux Therapeutics, Inc. (NASDAQ: JANX). It appears to be a financial data page from TradingView, providing an overview of the company's financial information, technical analysis, and market data. The content is prima", "url": "https://www.tradingview.com/symbols/NASDAQ-JANX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T03:40:15", "published_display": "04 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Janux Therapeutics, Inc. \u2013 NASDAQ:JANX", "summary": "This article provides financial information for Janux Therapeutics, Inc. (NASDAQ: JANX) focusing on its price to earnings forward metric. The content highlights a specific period, its value, and the percentage change. It appears to be an excerpt from a financial data platform lik", "url": "https://www.tradingview.com/symbols/NASDAQ-JANX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T21:39:22", "published_display": "03 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/janux-therapeutics-inc-janx-stock-130639551.html", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:06:39+00:00", "published_display": "30 Jun 2026 13:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2500 Growth Benchmark", "summary": "Janux Therapeutics, Inc. (JANX) has been removed from the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth, Russell 3000E Growth, and Russell Small Cap Comp Growth benchmarks. This news follows a series of recent updates including leadership changes, analyst pric", "url": "https://www.marketscreener.com/news/janux-therapeutics-inc-nasdaqgm-janx-dropped-from-russell-2500-growth-benchmark-ce7f5fdfdd89ff27", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:50:00", "published_display": "29 Jun 2026 19:50", "sentiment": "negative", "sentiment_pct": 32, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 3000 Growth Benchmark", "summary": "Janux Therapeutics, Inc. (NasdaqGM: JANX) has been removed from the Russell 3000 Growth Benchmark, as well as the Russell 2500, Russell 2000, and Russell 3000E Growth Benchmarks. This news follows several other recent updates for the company, including leadership changes, adjuste", "url": "https://www.marketscreener.com/news/janux-therapeutics-inc-nasdaqgm-janx-dropped-from-russell-3000-growth-benchmark-ce7f5fdcd188f72d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:09:47", "published_display": "29 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2000 Growth Benchmark", "summary": "Janux Therapeutics, Inc. (NasdaqGM:JANX) has been removed from the Russell 2000 Growth Benchmark as of June 29, 2026. The biopharmaceutical company is currently developing tumor-activated immunotherapies for cancer, utilizing its TRACTr, TRACIr, and ARM bispecific platforms. This", "url": "https://www.marketscreener.com/news/janux-therapeutics-inc-nasdaqgm-janx-dropped-from-russell-2000-growth-benchmark-ce7f5fded188f223", "source_name": "marketscreener.com", "published_at": "2026-06-29T11:41:50", "published_display": "29 Jun 2026 11:41", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Most Promising Cancer Stocks According to Wall Street Analysts", "summary": "This article identifies five promising cancer stocks according to Wall Street analysts, focusing on companies with significant price target upsides and pipeline developments. It highlights Janux Therapeutics, Inc. (NASDAQ:JANX) as one such company, detailing analyst ratings, its ", "url": "https://www.insidermonkey.com/blog/5-most-promising-cancer-stocks-according-to-wall-street-analysts-1790774/", "source_name": "Insider Monkey", "published_at": "2026-06-28T17:10:18", "published_display": "28 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in JANX Response", "summary": "Stock Traders Daily's Quantitative Research Desk has analyzed Janux Therapeutics Inc. (NASDAQ: JANX), identifying strong near and mid-term sentiment but a weak long-term outlook. The analysis highlights an exceptional risk-reward short setup targeting a 29.6% downside with minima", "url": "https://news.stocktradersdaily.com/news_release/34/Discipline_and_Rules-Based_Execution_in_JANX_Response_062726075202_1782561122.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-27T07:40:36", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JANX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Janux Therapeutics, Inc. (JANX) stock for 2027, based on analyst ratings and estimates. It includes current stock performance data, financial metrics like revenue and earnings, and answers frequently asked questions about the c", "url": "https://www.tradingview.com/symbols/NASDAQ-JANX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T11:09:49", "published_display": "26 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics, Inc. Actuals & Estimates (NASDAQ:JANX)", "summary": "This article provides an overview of Janux Therapeutics, Inc. (NASDAQ: JANX) stock, including its current price, performance, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue for past quarters, and also provides upcoming ea", "url": "https://www.tradingview.com/symbols/NASDAQ-JANX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:49", "published_display": "26 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX)", "summary": "Healthcare analysts have issued bullish sentiments for Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX). Debanjana Chatterjee from JonesTrading reiterated a Buy rating for Sionna with a $63.00 price target, while Supawat Thongthip from Truist Financial gave Janu", "url": "https://www.theglobeandmail.com/investing/markets/stocks/JANX/pressreleases/17357/analysts-offer-insights-on-healthcare-companies-sionna-therapeutics-inc-sion-and-janux-therapeutics-inc-janx/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T08:52:00", "published_display": "26 Jun 2026 08:52", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $26", "summary": "Truist Financial has initiated coverage on Janux Therapeutics (JANX.US) with a Buy rating. The firm has set a target price of $26 for the company's shares. This indicates a positive outlook from Truist Financial regarding Janux Therapeutics' future performance.", "url": "https://www.moomoo.com/news/post/72044984/truist-financial-initiates-janux-therapeutics-janxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-26T00:40:36", "published_display": "26 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (NasdaqGM:JANX) Stock Forecast & Analyst Predictions", "summary": "Janux Therapeutics (JANX) is forecast to experience a decline in earnings at 16.8% per annum, while revenue is expected to grow by 47.7% annually. The company, which is currently unprofitable, has seen various price target changes and estimate revisions from analysts. Recent upda", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-janx/janux-therapeutics/future", "source_name": "Simply Wall Street", "published_at": "2026-06-25T13:41:50", "published_display": "25 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Janux Therapeutics Inc For: 23 June By Investing.com", "summary": "This article announces that Janux Therapeutics Inc. filed a Form 8K for June 23. This is a brief notice from Investing.com, highlighting the company's regulatory filing. The notice includes their stock symbol JANX and its recent performance.", "url": "https://au.investing.com/news/stock-market-news/form-8k-janux-therapeutics-inc-for-23-june-93CH-4501037", "source_name": "Investing.com Australia", "published_at": "2026-06-24T23:41:45", "published_display": "24 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMO exits Janux Therapeutics (NASDAQ: JANX) as company starts search", "summary": "Janux Therapeutics announced the departure of its Chief Medical Officer, William Go, M.D., Ph.D., on June 23, 2026. The company stated his departure was a termination without \"Cause\" and does not reflect any disagreement over operations or strategy. Janux will begin a search for ", "url": "https://www.stocktitan.net/sec-filings/JANX/8-k-janux-therapeutics-inc-reports-material-event-a78f4c35970f.html", "source_name": "Stock Titan", "published_at": "2026-06-23T19:40:17", "published_display": "23 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Inc (JANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on Janux Therapeutics Inc. (JANX)'s revenue breakdown, but states that the relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It provides current stock information fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-janx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:11:31", "published_display": "17 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides an overview of Janux Therapeutics Inc. (JANX) regarding its dividends and stock splits. It states that the company has not distributed any dividends over the past five years and has no historical stock split data available. Financial data for JANX, including ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-janx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:11:31", "published_display": "17 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Inc (JANX) Institutional Confidence", "summary": "Janux Therapeutics Inc (JANX) has an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 110.21%, showing a 0.64% increase quarter-over-quarter. Steven Cohen", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-janx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T23:10:58", "published_display": "16 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Inc (JANX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Janux Therapeutics Inc (JANX) has a risk assessment score of 2.93, ranking 175 out of 388 in the Biotechnology & Medical Research industry, with a beta of 2.54 indicating higher volatility than the S&P 500. The company's risk profile includes a 240-day maximum drawdown of +64.94%", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-janx/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-16T23:09:46", "published_display": "16 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JANX SEC Filings - Janux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Janux Therapeutics (JANX) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It highlights recent filings such as Janus Henderson's passive ownership report, Adage Capital's stake", "url": "https://www.stocktitan.net/sec-filings/JANX/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-15T00:10:03", "published_display": "15 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Reports Results of 2026 Annual Meeting", "summary": "Janux Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026, where shareholders elected two Class II directors, ratified Ernst & Young LLP as the independent accounting firm, and approved executive compensation. The company's stock, JANX, currently hold", "url": "https://www.theglobeandmail.com/investing/markets/stocks/JANX/pressreleases/2458085/janux-therapeutics-reports-results-of-2026-annual-meeting/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T09:40:46", "published_display": "14 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (JANX) director reports RSU and option awards tied to RA Capital", "summary": "Janux Therapeutics director Jake Simson reported receiving 5,500 restricted stock units (RSUs) and options for 15,500 shares, with vesting tied to continuous service. These equity awards are held for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund II, aligning", "url": "https://www.stocktitan.net/sec-filings/JANX/form-4-janux-therapeutics-inc-insider-trading-activity-c7f52f7a8e0b.html", "source_name": "Stock Titan", "published_at": "2026-06-13T06:40:20", "published_display": "13 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (JANX) director awarded RSUs and stock options", "summary": "Janux Therapeutics director Natasha Hernday received 5,500 restricted stock units (RSUs) and stock options for 15,500 shares. The RSUs vest by June 11, 2027, or the next annual stockholder meeting, while the stock options vest monthly over 12 months from June 11, 2026, both subje", "url": "https://www.stocktitan.net/sec-filings/JANX/form-4-janux-therapeutics-inc-insider-trading-activity-b29ae949f07b.html", "source_name": "Stock Titan", "published_at": "2026-06-13T06:40:20", "published_display": "13 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director of Janux Therapeutics (JANX) receives new RSU and stock option awards", "summary": "Winston Kung, a director at Janux Therapeutics (JANX), has received new equity awards comprising 5,500 restricted stock units (RSUs) and 15,500 stock options with an exercise price of $13.66 per share. The RSUs are set to vest by June 11, 2027, or the next annual stockholder meet", "url": "https://www.stocktitan.net/sec-filings/JANX/form-4-janux-therapeutics-inc-insider-trading-activity-2d58852db0b3.html", "source_name": "Stock Titan", "published_at": "2026-06-13T00:10:09", "published_display": "13 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Janux Therapeutics (JANX) gets new RSUs and stock options", "summary": "Janux Therapeutics director Vickie L. Capps was granted 5,500 restricted stock units (RSUs) and options for 15,500 shares of common stock at an exercise price of $13.66 per share. Following these awards, her direct holdings increased to 79,598 shares. The RSUs and stock options a", "url": "https://www.stocktitan.net/sec-filings/JANX/form-4-janux-therapeutics-inc-insider-trading-activity-1220f455fb5c.html", "source_name": "Stock Titan", "published_at": "2026-06-13T00:10:09", "published_display": "13 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Highlights 1st ASCO Abstract Acceptance", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/akari-therapeutics-highlights-1st-asco-223346398.html", "source_name": "IPO-Edge.com", "published_at": "2026-05-28T22:33:46+00:00", "published_display": "28 May 2026 22:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPTWhweV9vbVpoeFI4NGRyYzhDT1JRNVEzV1g1V2ZXTndlLWVpQmk2OGs1czczT3lORVphM1pCUDF1OUl5ZGtEamdmdHpEQW10aXlYVUdEaGxUd0RuLU44cmVtY0I5eFdqSXVsR1c1T2VHYlZfS1k1MUp4enVPX2ZZRk5BTUYzdy10VFVJT1ZLeHRhZUxFRGtDM0ZVdEpRZw?oc=5", "source_name": "Market source", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (JANX) Losses Reach US$113.6 Million TTM Reinforcing Bearish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Raises Janux Therapeutics Price Target to $30 From $27, Keeps Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-raises-janux-therapeutics-price-164408818.html", "source_name": "MT Newswires", "published_at": "2026-05-08T16:44:08+00:00", "published_display": "08 May 2026 16:44", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNSXdZWlVkX2xXcnZBeDFzZ09YY0pqUTJDVE8xSjh2WXl6dk16c3NucHhzcUU5ZHRpRzZuNDlRSHBUb0VHc0dpQ1VJbFdJMDNxaGdhbktwbkU3X24yYnJnMHJ5WjB0S25MbmEyd3NqdHIxTjBkckFvV1IzU2ZoLUlraUhmdGtlWnYtWEc1U1lGUHRQQVF0Z0ZwdkxKN0pQNzUwRjlBOUpnSVgyQVNzWERiT09uNVRLM2ZLb0NRME13elphUQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPN2syQVVRcm85Q1BsNUtQeDN1aUNVMGFvYmNjZG9YdW9MTjFzUXp1RnkzemtaUkNfRXBuZFd0Z2xtb1gxUk1BNkpBU094dDlEMGJ4UE9ZR29tbktnajlyeUhmSGNXT2pCRWZlZ1BWMU9lbU5nM0ZQSmR3YWI3T29jREE0enhFdlpQRXVNY1JhamtVbko0WFdfYVlDMmtsRk1lU3BYN01ydG4tRlY0cUl5ejc2ZV9kMF9qM3FFMHRYczBvYy1xdndkZ2FOeWdobXFLOVlORUFEVU5DOEhI?oc=5", "source_name": "Business Wire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOOFJuQmxYRk8wdnlkX0ZDamRNXy16OUg1YzZqMTQ1eVZhZm5tSmFzUmVsOGVfSk94VS11THNBOEc5THZDY18tUC0xTU5SMlZmdklOQXFLbjRteXRNRVk5RWtlbUtJQ0F2QWxMdmwtS1NVTE5LdjFncmFkTzctcFNCN19GWXpjQ1pQaFFJRTd3akVVcTVFT09jUy1fX2dmN3J1Q1JtS0J1aw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMWRJSnQ2LUp0NDdNZkhFcTg2dzliZHVLSFVpamFRY1ZHOXlBa0dEcHkwcFZPTWRySWN6X1RPVXZoUTZLcXR3NjNzbmZRbzRmY2NSN3N2Yl90ZEZscDBjWmNhVWUyRW1UdGgtZC1EWmllOE5jVmF3MWhuek9oRHgtMWZPRWxfZENfdFFxQ3VLZUNmZTNVemtob0pXdXowcmFuYkpqQUlEVGxTeU9MTlp4OEVkbHZEdmdKTVhZbFN3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Multiple Insiders Sold Janux Therapeutics Shares Presenting Weak Signs For Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux drops JANX008 cancer program after Phase 1a data review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQXZzTVlRaGl5R2E3Q3BwWnljdlgtUm03NFMwN041OGVtSDZvTW8tREgxWTUwQkt1VmozLVJuSkxWZVFSUEVYVXlibVNSN1FaQUtZbG5VTFRiUHJKQTBZZUU4THlGWTJ0Mk02MUF6T2NnbEg3QmRpSjdaRXpSLW13TWZkc2lfTU5MaEhQNE1PeUdjTnB1M1d4YU1hZnNkV1FpSHMtYTdBWmNOMWxZMFBSR2l5dlYtRmY1TldB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New prostate cancer drug candidate enters first human trial at Janux", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNdjNfZWwtbXVfQ2tlOGwzVnFFeFo2N2steDE0c2xsTzc5eXhsXzc5emY3S2MyQzVudWFmcXJFdExPMFNKaGlxTG5kaVcyMktHR1BsYi0ySTVmWTl5RGl0dklMeUNhaF9TRVF1X3ZxbC1TbWNqOGlyY0Z5M1VBa3NtVzZxeUxkUXQ2N0lkd2p3R1Q4TVJMZkJGTEp2ZHVTOHJLTC1ib05XYnhCNUpKTnM1cVpCR0RLQ3djZUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Secures $35M Milestone Payment From BMY Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNVk1DYjc2M2FKREdCeXg4WmNwRTZwUEg5TWlYRUJvOEU2bGJpaTFQc25iMzFrTjRCOWROamFvQjNPcG1sNXY5LVdRV0RoMVNhMlZFeFpxNzJ5aUpSV3RtMWlfNjY0M0lrZFlRbFo5S3JZNVhtQWhsQXZKZnMtMkpDMmxJa2pVUEFscHR0UlVfVXpuSGhfZTRBa1ZWX2stY1FabzZsRTdFUVhqT2F1bkE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Where is Janux Therapeutics (JANX) Headed According to Analysts?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOR3FTMDlSUE1uYXcySDV5WVd0WWgzbnQ5RUN3YmtvWGN3cjVIMlRFOTJidHlleGk1bFNKUkNFcTM2QzQtZGJGdjJfX0FFcGRaTEU2bjhoRVlVeTBHODNET0FLU1hHTDJPY0lMc3I0VEtsaDNrbV9SUFhtbVcwZlR2V2NibzBJUlhEb3c?oc=5", "source_name": "Market source", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNNVZ6LVNlY0k3S284VzdUUzJPSFhpRFgwLVF3R2JHMlNzOEpNbTg2ZjhNdXhaT1JFLVpMbXdVTFNFeUFtbHhwZHM4UkJLWktrbHpOaXpHNWZ2YnJVaXdTM3Z0cHJjam9QNjdjR1ktRkVndTVxUWdOS2FjVVRSUktLQWRGcnJHcVB0bGR1Y0pGR25tZkdjckNCUVV2Qjc5VEFYS290UDlBaVRSbFNXRnBjVng3TFVUM1dtOWV1X0l2ZUo?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-22T13:03:08+00:00", "published_display": "22 Jan 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reassessing Janux Therapeutics (JANX) Valuation After Mixed Market Reaction to New JANX007 Phase 1 Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street \u2014 Retail Sees A FOMO-Fueled Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNNThHY25iWWdmYUJ6a1Q1Um1FcjZKVkFwYS1BS3R3Q0FTc3JCSjVHYWRVVG5zLVhqSzdua3Q4cDV1SGFmbGY5NHlPQVI2Rkx6V0JCQUVJeW1nTWk3T0dRZ1hVeUpsUTdPVG95Vm9XVHhhNTh3TWNiX2hiNTBtOE4xX1daaUxEVzlBQTlDZVdXZ0JmZG1xTFBqazlrNnRudUFpdzY5MUpTNldUVjc2cGdFQ1RjMjdfM0JNU0ZraloxR1Y2WFJpLXBrOWpwcVk3TEx0S3BESWNMQUY2OEVWNHp5dDlHU3JtSXdFVkVxN1Jocm1mNU0wZmptUA?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-02T16:38:25+00:00", "published_display": "02 Dec 2025 16:38", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janux Therapeutics (JANX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE84bFB5ZklSR2ZoTkRGVklIMmlSbjI4ZVdNc0prMUp4aDBkY0dGU2tsVEdadDRuclhELXRXWTN4WDBtNUlJSzUtLU1NaFg4cEhJcjBj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:19:23+00:00", "published_display": "25 Apr 2025 01:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JANX Stock Price and Chart \u2014 NASDAQ:JANX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE11RlkzUjc4b28xYjMwMEtCQ1Y2ZHh2ZUtfQjYtMEIxNm16cURCRVFUWGdGZ1FJVlRSUm53ZUJtbHNONlZOdVA1TDE1bEJXNno4WWZlQXRGNGtXem9R?oc=5", "source_name": "TradingView", "published_at": "2021-06-11T02:37:11+00:00", "published_display": "11 Jun 2021 02:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 60, "sentiment_summary": {"positive": 14, "negative": 9, "neutral": 37, "score": 52, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.45, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 16.26, "latest_week": "2026-07-17", "one_week_move": -0.9, "four_week_move": 14.3, "twelve_week_move": 8.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.164022, "market_dynamics_buy_signal": false, "relative_strength": -22.145004, "fair_value_gap": -40.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.2872, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.9% over one week, +14.3% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 49, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 10}, {"label": "simplywall.st", "count": 8}, {"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 4}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Simply Wall Street", "count": 2}, {"label": "Insider Monkey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 7}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.9% over one week, +14.3% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Avoiding Lag: Real-Time Signals in (JANX) Movement"}], "updated_at": "2026-07-22T13:32:13.948026+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}